



ASX Announcement

IMRICOR SUCCESSFULLY COMPLETES PLACEMENTS AND ACCELERATED INSTITUTIONAL ENTITLEMENT OFFER

5 February 2024 – Melbourne, Australia (4 February 2024 – Minneapolis, United States) – Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) is today pleased to announce it has received firm commitments for its institutional placement (**Institutional Placement**), placement to US investors (**US Placement**) and the institutional component (**Institutional Entitlement Offer**) of its 1 for 7.5 pro-rata accelerated non-renounceable entitlement offer (**Entitlement Offer**) of new CHESS Depository Interests (**New CDIs**), announced on Friday, 2 February 2024.

The Institutional Placement, US Placement and Institutional Entitlement Offer will raise approximately A\$8.0 million in total at an issue price of A\$0.45 per CDI and share (**Offer Price**). The offer was well supported by existing shareholders as well as attracting new institutional shareholders to the register.

Executive Chair, President and CEO Steve Wedan said "I would like to acknowledge the ongoing support from our key institutional shareholders who have participated and welcome new investors in the accelerated component of our placement and entitlement offer. The funds raised will allow Imricor to achieve many significant milestones in 2024, including the growth of commercial procedures and revenue in the EU and Middle East, the launch of our products across Australia and New Zealand, and the commencement of two global clinical trials: VISABL-AFL to support FDA approval in the US, and VISABL-VT to support expanding the Vision-MR Ablation Catheter's approved indications for use."

The New CDIs subscribed for under the Institutional Placement, US Placement and Institutional Entitlement Offer are expected to be settled on Friday, 9 February 2024 and be issued and commence trading on ASX, on Monday, 12 February 2024.

As a result of the successful completion of the Institutional Entitlement Offer, the Company's CDIs will recommence normal trading on an ex-entitlement basis from the opening of the market on Monday, 5 February 2024.

Morgans Corporate Limited is acting as sole lead manager for the Entitlement Offer and the Institutional Placement.

Retail Entitlement Offer

The retail component of the Entitlement Offer (**Retail Entitlement Offer**), at the same Offer Price, will open at 9:00am (AEDT) on Thursday, 8 February 2024 and close at 5:00pm (AEDT) on Thursday, 22 February 2024. A maximum of approximately A\$7.1 million is able to be raised under the Retail Entitlement Offer.

The Retail Entitlement Offer will be made to all securityholders (**Eligible Retail Securityholders**) who:

- are registered as holders of CDIs as at 7.00pm (AEDT) on Tuesday, 6 February 2024 (being the Record Date);



- have a registered address on Imricor's CDI register in Australia or New Zealand;
- are not in the United States and are not a person (including nominees or custodians) acting for the account or benefit of a person in the United States;
- were not invited to participate in the Institutional Entitlement Offer and were not treated as an ineligible institutional securityholder under the Institutional Entitlement Offer; and
- are eligible under all applicable securities laws to receive an offer under the Retail Entitlement Offer.

Securityholders with a registered address outside Australia or New Zealand are considered ineligible securityholders and cannot participate in the Retail Entitlement Offer.

All eligible directors of the Company intend to take up their full entitlements under the Retail Entitlement Offer.

Further details about the Retail Entitlement Offer will be contained in the Retail Entitlement Offer Booklet, which is expected to be lodged on ASX on Thursday, 8 February 2024 (AEDT). Eligible Retail Securityholders wishing to participate in the Retail Entitlement Offer should carefully read the Retail Entitlement Offer Booklet before making any investment decision regarding the Retail Entitlement Offer.

Key dates for the Entitlement Offer*

Key Events	Date
Announcement of Institutional Entitlement Offer results; voluntary suspension lifted	Monday, 5 February 2024
Record date for Retail Entitlement Offer	7:00pm on Tuesday, 6 February 2024
Retail Entitlement Offer opens; dispatch of Retail Offer Booklet	Thursday, 8 February 2024
Settlement of New CDIs issued under Institutional Entitlement Offer	Friday, 9 February 2024
Allotment and normal trading of New CDIs issued under Institutional Entitlement Offer	Monday, 12 February 2024
Retail Entitlement Offer closes	Thursday, 22 February 2024
Announcement of Retail Entitlement Offer results	Tuesday, 27 February 2024
Allotment of New CDIs under Retail Entitlement Offer	Wednesday, 28 February 2024
Retail Entitlement Offer New CDIs commence trading on ASX	Thursday, 29 February 2024



Dispatch of holding statements to Retail Entitlement
Offer participants

Thursday, 29 February 2024

* Please note the dates set out above are indicative only and are subject to change. All dates and times are references to Melbourne, Australia time.

Authorised for release by Steve Wedan, Executive Chair, President, and CEO.

ENDS

Further Information

Investors:

Steve Wedan
Executive Chair, President and CEO
Email: steve.wedan@imricor.com

Media:

Simon Hinsley
Executive Director, NWR
Email: simon@nwrcommunications.com.au
Mobile: +61 401 909 653

About Imricor

Imricor Medical Systems, Inc. (ASX:IMR) is a leading developer of innovative MRI-compatible medical devices which can be used to carry out MRI-guided cardiac catheter ablation procedures. Headquartered in the US, Imricor seeks to make a meaningful impact on patients, healthcare professionals, and healthcare facilities around the world by increasing the success rates and bringing down the overall costs of cardiac catheter ablation procedures.

Imricor's Products

Imricor is a pioneer and leader in developing MRI-compatible products for cardiac catheter ablation procedures, and believes it is the first company in the world to bring commercially viable and safe MRI-compatible products to the cardiac catheter ablation market.

The Vision-MR Ablation Catheter is the Company's prime product offering, specifically designed to work under real-time MRI guidance, with the intent of enabling higher success rates along with a faster and safer treatment compared to conventional procedures using x-ray guided catheters. The Vision-MR Ablation Catheter has been approved in the European Union with an indication for treating type 1 atrial flutter. Imricor intends to seek approval for expanded indications in the future. The Company is also in the early stages of pursuing the required regulatory approvals to place its key products on the market in Australia and the U.S.

The Company has also obtained approval within the EU for the sale of the Advantage-MR EP Recorder/Stimulator System and its consumable product, the Vision-MR Dispersive Electrode.

Imricor sells its capital and consumable products to hospitals and clinics for use in Interventional Cardiac Magnetic Resonance Imaging (iCMR) labs, in which ablation procedures using the Vision-MR Ablation Catheter can be performed. An iCMR lab is an interventional lab that is fitted with MRI equipment for use in cardiac diagnostic and interventional procedures. The installation of iCMR labs is driven primarily by MRI equipment vendors working collaboratively with Imricor. Vendors such as Koninklijke Philips N.V. and Siemens Healthcare GmbH help to target certain sites and support the design and construction of iCMR labs for those sites.

Foreign Ownership Restrictions

Imricor's CHES Depository Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This



designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on the Company's management's beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, EU commercial market acceptance and EU sales of our product as well as our expectations with respect to our ability to develop and commercialise new products. Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Imricor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Imricor may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.